Human bcl-2 expression, cleaved caspase-3, and KSHV LANA-1 in kaposi sarcoma lesions

American Journal of Clinical Pathology

Volumn 128, Issue 5, 2007, Pages 794-802

  Da Silva, Suzane Ramos ^a   Bacchi, Maura M ^b   Bacchi, Carlos E ^b   De Oliveira, Deilson Elgui ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Consultoria em Patologia ^*  (Brazil)

Author keywords

Cleaved caspase 3; HHV 8; Human bcl 2; Human herpesvirus 8; Kaposi sarcoma; Kaposi sarcoma associated herpesvirus; KSHV; Latency associated nuclear antigen 1

Indexed keywords

CASPASE 3; LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IATROGENIC DISEASE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, VIRAL; APOPTOSIS; BRAZIL; CASPASE 3; DNA, VIRAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HERPESVIRUS 8, HUMAN; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SARCOMA, KAPOSI; SKIN NEOPLASMS; VIRAL PROTEINS;

EID: 36249029262     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/TFU2FXK3AP0C9R2X     Document Type: Article

References (51)

1. Kaposi M. Idiopathisches multiples pigmentsarkom der Haut. Arch Dermatol Syph. 1872;4:265-272.
2. Ensoli B, Sgadari C, Barillari G, et al. Biology of Kaposi's sarcoma. Eur J Cancer. 2001;37:1251-1269.
3. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases: part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2002;2:281-292.
4. Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol. 1990;22:1237-1250.
5. Kempf W, Adams V. Viruses in the pathogenesis of Kaposi's sarcoma: a review. Biochem Mol Med. 1996;58:1-12.
6. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342:1027-1038.
7. Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc. 2002;77:941-949.
8. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335:123-128.
9. Boshoff C. Kaposi's sarcoma: coupling herpesvirus to angiogenesis. Nature. 1998;391:24-25.
10. Whelan P, Scadden DT. New developments in the etiopathogenesis and treatment of HIV-related Kaposi's sarcoma. Clin Dermatol. 2000;18:469-477.
11. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
12. Friborg J Jr, Kong W, Hottiger MO, et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889-894.
13. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 2000;6:1121-1127.
14. An J, Lichtenstein AK, Brent G, et al. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 2002;99:649-654.
15. Hyun TS, Subramanian C, Cotter MA II, et al. Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol. 2001;75:8761-8771.
16. Benedict CA, Norris PS, Ware CF. To kill or be killed: viral evasion of apoptosis. Nat Immunol. 2002;3:1013-1018.
17. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543-8567.
18. Kieff E, Shenk T. Modulation of apoptosis by herpesviruses. Semin Virol. 1998;8:471-480.
19. Meinl E, Fickenscher H, Thome M, et al. Anti-apoptotic strategies of lymphotropic viruses. Immunol Today. 1998;19:474-479.
20. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
21. Sun R, Lin S-F, Staskus K, et al. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol. 1999;73:2232-2242.
22. Jenner RG, Boshoff C. The molecular pathology of Kaposi's sarcoma-associated herpesvirus. Biochim Biophys Acta. 2002;1602:1-22.
23. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-194.
24. Barinaga M. Cell suicide: by ICE, not fire. Science. 1994;263:754-756.
25. Desagher S, Martinou J-C. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 2000;10:369-377.
26. Ramos-da-Silva S, Elgui-de-Oliveira D, Borges L, et al. Kaposi's sarcoma-associated herpesvirus infection and Kaposi's sarcoma in Brazil. Braz J Med Biol Res. 2006;39:573-580.
27. Greer CE, Lund JK, Manos MM. PCR amplification from paraffin-embedded tissues: recommendations on fixatives for long-term storage and prospective studies. PCR Methods Appl. 1991;1:46-50.
28. Pan L, Milligan L, Michaeli J, et al. Polymerase chain reaction detection of Kaposi's sarcoma-associated herpesvirus-optimized protocols and their application to myeloma. J Mol Diagn. 2001;3:32-38.
29. Katano H, Sato Y, Kurata T, et al. High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J Pathol. 1999;155:47-52.
30. Katano H, Sato Y, Sata T. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer. 2001;92:3076-3084.
31. Neipel F, Fleckenstein B. The role of HHV-8 in Kaposi's sarcoma. Semin Cancer Biol. 1999;9:151-164.
32. Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol. 1998;79:1573-1591.
33. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet. 1995;346:799-802.
34. Chuck S, Grant RM, Katongole-Mbidde E, et al. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis. 1996;173:248-251.
35. Blasig C, Zietz C, Haar B, et al. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol. 1997;71:7963-7968.
36. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet. 1996;348:858-861.
37. Koelle DM, Huang ML, Chandran B, et al. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis. 1997;176:94-102.
38. Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338:948-954.
39. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156:743-749.
40. Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases. Am J Surg Pathol. 2003;27:1546-1550.
41. Ciufo DM, Cannon JS, Poole LJ, et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol. 2001;75:5614-5626.
42. Vassallo J, Rebouças I, Brousset P. Detection of HHV-8 in reactive lymphoid tissue of patients from Sao Paulo State, Brazil [letter]. J Clin Pathol. 2002;55:78-79.
43. Watanabe T, Sugaya M, Atkins AM, et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol. 2003;77:6188-6196.
44. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays. 2000;22:1007-1017.
45. Dada MA, Chetty R, Biddolph SC, et al. The immunoexpression of bcl-2 and p53 in Kaposi's sarcoma. Histopathology. 1996;29:159-163.
46. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol. 1998;22:863-872.
47. Kennedy MM, O'Leary JJ, Oates JL, et al. Human herpes virus 8 (HHV-8) in Kaposi's sarcoma: lack of association with bcl-2 and p53 protein expression. Mol Pathol. 1998;51:155-159.
48. Morris CB, Gendelman R, Marrogi AJ, et al. Immunohistochemical detection of bcl-2 in AIDS-associated and classical Kaposi's sarcoma. Am J Pathol. 1996;148:1055-1063.
49. Fernandez-Figueras MT, Puig L, Fernandez-Vasalo A, et al. Immunohistochemical detection of bcl-2 in Kaposi's sarcoma lesions varies according to histopathologic stage, whereas expression of bcl-x and mcl-1 differs according to human immunodeficiency virus serologic status of patients. Mod Pathol. 2000;13:438-445.
50. Simonart T, Degraef C, Noel JC, et al. Overexpression of bcl-2 in Kaposi's sarcoma-derived cells. J Invest Dermatol. 1998;111:349-353.
51. Nor JE, Christensen J, Liu J, et al. Up-regulation of bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001;61:2183-2188.